NASDAQ:CRBU Caribou Biosciences Q2 2025 Earnings Results & Report $0.37 -0.01 (-1.63%) As of 12:38 PM Eastern This is a fair market value price provided by Massive. Learn more. Caribou Biosciences beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$0.35 versus the -$0.40 consensus estimate, while revenue of $2.67 million topped the $1.64 million estimate by $1.02 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 12, 2025TimeBefore Market OpensConference Call7:00 AM ET Caribou Biosciences EPS ResultsActual EPS-$0.35Consensus EPS -$0.40Beat/MissBeat by +$0.05One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersCaribou Biosciences Revenue ResultsActual Revenue$2.67 millionExpected Revenue$1.64 millionBeat/MissBeat by +$1.02 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Caribou Biosciences Q2 2025 Earnings FAQ Did Caribou Biosciences beat earnings estimates for Q2 2025? Caribou Biosciences (NASDAQ:CRBU) reported earnings of -$0.35 per share for Q2 2025, beating the consensus estimate of -$0.40. The report was announced on Tuesday, August 12, 2025. What was Caribou Biosciences' revenue for Q2 2025? Caribou Biosciences reported revenue of $2.67 million for Q2 2025, against a consensus estimate of $1.64 million. Caribou Biosciences Earnings HeadlinesCaribou Biosciences (CRBU) forms hammer chart pattern: Time for bottom fishing?November 12 at 2:42 PM | msn.comCaribou Biosciences (CRBU) Stock Sees Fair Value Cut After Clinical Programs HaltedNovember 12 at 9:12 AM | finance.yahoo.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 13 at 1:00 AM | Behind the Markets (Ad)Caribou Biosciences Reports Third Quarter 2026 Financial ResultsNovember 5, 2026 | finance.yahoo.comCaribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Beats Revenue EstimatesNovember 5, 2026 | finance.yahoo.comCaribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual MeetingNovember 4, 2026 | globenewswire.comSee More Caribou Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Caribou Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Caribou Biosciences and other key companies, straight to your email. Email Address About Caribou BiosciencesCaribou Biosciences (NASDAQ:CRBU) is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. Its work focuses on allogeneic, or donor-derived, CAR-T cell treatments designed to be manufactured for use by multiple patients. The company uses its chRDNA genome-editing platform, which combines CRISPR RNA with DNA components, to make targeted changes to cells. Its clinical programs include CAR-T candidates directed at targets such as CD19 and BCMA, which are being developed for certain blood cancers. Founded in 2011 and based in Berkeley, California, Caribou grew out of research into CRISPR genome-editing technology. Co-founder Rachel Haurwitz serves as the company’s president and chief executive officer.View Caribou Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
